Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period. Enanta is a biotechnology company developing small-molecule therapies for liver diseases and viral infections. This fiscal first quarter of 2018 covers the three months ended December 31, 2017; comparisons are with the three months ended December 31, 2016. Its sole revenue-generating arrangement is its collaboration with AbbVie, which commercializes HCV regimens containing Enanta-discovered protease inhibitors.
Financial performance and position
| Metric | Q1 FY2018 | Prior-year quarter |
|---|---|---|
| Revenue | $38.1 million | $10.4 million |
| Royalties | $23.1 million | $10.4 million |
| Milestone revenue | $15.0 million | None |
| Research and development expense | $18.0 million | $12.5 million |
| General and administrative expense | $5.8 million | $4.9 million |
| Operating income (loss) | $14.4 million | $(7.0) million |
| Net income (loss) | $11.7 million | $(5.0) million |
| Diluted earnings (loss) per share | $0.59 | $(0.26) |
| Cash provided by operating activities | $4.4 million | $3.1 million |
- Revenue increased approximately 266% year over year; royalties increased approximately 122%. The quarter’s $15.0 million milestone followed Japanese commercialization approval for MAVIRET and was the last available glecaprevir commercialization milestone under the agreement.
- Operating margin was approximately 37.7% and net margin approximately 30.7%, benefiting from the milestone revenue. The filing does not report gross margin.
- At December 31, Enanta held $68.1 million in cash and cash equivalents and $229.4 million in marketable securities, or $297.5 million combined. Current assets were $247.6 million and current liabilities $19.2 million; the current ratio was approximately 12.9.
- Total liabilities were $23.1 million. Enanta reported no debt outstanding other than its capital lease obligation; that obligation was $0.36 million. Stockholders’ equity was $317.6 million.
- Operating cash flow was positive, but the $12.5 million increase in accounts receivable was a significant working-capital use. Cash and cash equivalents increased $2.4 million during the quarter.
Material changes and notable items
- Enanta moved from a year-ago operating and net loss to profit, principally as royalty revenue rose and the Japan milestone was recognized. The milestone is non-recurring; royalties accounted for $23.1 million of current-quarter revenue.
- R&D expense rose approximately 43%, mainly due to increased clinical and preclinical activity and supporting headcount. Liver-disease R&D expense increased to $10.7 million from $5.9 million; virology expense was $7.2 million versus $6.5 million.
- Income tax expense was $3.6 million, compared with a $1.5 million benefit in the prior-year quarter. Current-quarter expense included a $3.9 million reduction in deferred tax assets following the Tax Act’s federal corporate tax-rate reduction.
- Warrants to purchase Series 1 preferred stock expired or were exercised in October 2017; none remained outstanding at quarter-end. Preferred stock remained classified as a liability at $1.5 million.
Outlook, management commentary, and risks
- Management said existing cash, cash equivalents, marketable securities, and expected cash flows should fund operations for the foreseeable future. No numerical revenue, earnings, or cash-burn guidance was provided.
- Management expects R&D expense to increase in fiscal 2018 as clinical studies advance. EDP-305 entered Phase 2 studies in PBC and NASH; EDP-938 entered Phase 1, with a Phase 2a RSV challenge study anticipated in the second half of 2018. The company also aimed to identify an HBV development candidate in 2018.
- Enanta’s near-term revenue depends on AbbVie’s HCV sales, market share, pricing, reimbursement, and commercialization decisions. MAVYRET/MAVIRET launched at a lower list price than AbbVie’s earlier HCV regimens, and management said it was too early to assess the success of AbbVie’s market-share strategy.
- Material risks include HCV market competition and pricing pressure; reliance on AbbVie; clinical, regulatory, manufacturing, and trial-enrollment uncertainty for Enanta’s own candidates; and the possibility of needing additional financing if collaboration royalties weaken or development costs rise.
- The company reported no threatened or pending litigation. The IRS was examining fiscal 2016, with no adjustments proposed to date. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Subsequent AbbVie HCV sales, product mix, pricing, reimbursement, and Enanta’s royalty receipts—particularly as MAVYRET/MAVIRET competes with other HCV therapies.
- Whether clinical enrollment, safety, and efficacy support the stated EDP-305 and EDP-938 development plans and the targeted HBV candidate timeline.
- Future R&D spending, operating cash flow, accounts-receivable collections, and management’s assessment of cash runway.
- Any revisions to the Tax Act accounting estimate, including the deferred-tax-asset revaluation, and the outcome of the IRS examination.
- The filing’s reported figures are unaudited interim results; management cautioned that the quarter’s results are not necessarily indicative of subsequent quarters or the full fiscal year.